Immune cell therapy shows promise for hard-to-treat melanoma
NCT ID NCT00338377
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This study tests whether giving patients their own specially grown immune cells (T cells) along with high-dose IL-2 can fight metastatic melanoma. Some patients also receive a dendritic cell vaccine to help the T cells last longer. The trial includes several groups to explore different ways of delivering the cells, including directly into the spinal fluid. The goal is to shrink tumors and improve survival, though ongoing treatment may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.